Page 9 - Dror Bashan News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX – Get Rating) – Analysts at Zacks Investment Research issued their Q2 2022 earnings estimates for Protalix BioTherapeutics in a note issued to investors on Tuesday, May 17th. Zacks Investment Research analyst J. Vandermosten forecasts that the company will earn ($0.18) per share for the quarter. Zacks Investment Research also issued […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

Protalix BioTherapeutics Inc. (NYSE:NYSE:PLX) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET Company Participants Alexandra Schuman - LifeSci Advisors, IR Dror Bashan - President...

Protalix BioTherapeutics, Inc. (NYSEAMERICAN:PLX – Get Rating) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 5,650,000 shares, an increase of 39.5% from the March 31st total of 4,050,000 shares. Based on an average daily volume of 3,680,000 shares, the short-interest ratio is […]

The positive data from the Phase III BALANCE study is expected to support the resubmission of a Biologics License Application for PRX-102.